Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation ...(willaddress the crucial issues surroundi...),Health

-- What first and second generation nanotechnology products already are on the market, and what is to come?

-- Is Congress ready to act on nanotechnology if federal regulators do not?

-- Do Europe and Asia approach nanotechnology safety and oversight differently than the United States?

-- How do consumers see nanoproducts?

-- When it comes to nanotechnology, should size make a regulatory difference?

Michael Taylor, Research Professor of Health Policy, School of Public Health and Health Services, The George Washington University, and author of the most comprehensive report published on nanotechnology regulation at FDA, Regulating the Products of Nanotechnology, Does FDA Have the Tools It Needs?, will present the keynote address. Also, Sen. Ron Wyden (D-Ore.), co-chair of the Congressional Nanotechnology Caucus, and invited luncheon speaker, will discuss future congressional actions in this area.

Top-level FDA officials, including Associate Commissioner for Science Norris Alderson; Deputy Commissioner for Policy Randall W. Lutter; Deputy Associate General Counsel Jeffrey Senger; and Director of Food Additive Safety Laura Tarantino, will appear on a special panel on FDA regulation of nanotechnology.

Other featured speakers and moderators include:

Jay M. Ansell, Personal Care Products Council;

Susan D. Brienza, Of Counsel, Patton Boggs LLP;

George Burdock, President, Burdock Group;

Robert W. Carpick; University of Pennsylvania Director, The Nanotechnology Institute;

Ricardo Carvajal; Counsel, Reed Smith LLP;

Jim Czaban, Partner, WilmerHale;

Lee Farrow, Senior Vice President, ACE Medical Risk;

Piotr Grodzinski, Director, NCI Alliance for Nanotechnology in Cancer, NIH;

Ralph Hall, Professor, University of Minnesota Law School;

Robert A. Hoer
'/>"/>